certepetide

Certepetide (LSTA1, formerly CEND-1) is a cyclic peptide designed to open a transient delivery channel into tumors so co-administered chemotherapy actually reaches cancer cells. Lisata Therapeutics is the lead developer. The program has unwound: the lead Phase 2 in advanced cholangiocarcinoma (BOLSTER) was terminated early [1]; Lisata and Qilu Pharmaceutical mutually terminated their Greater China license in January 2026, with Qilu agreeing only to wind down its ongoing Phase 2 rather than fund new work [2][9]; and Lisata agreed to be acquired by Kuva Labs in March 2026 at $4.00 per share plus a contingent value right (CVR, a payment that only triggers if certepetide hits specified clinical or regulatory milestones) worth up to an additional $3.00 per share [4]. That deal collapsed on July 20, 2026 when Kuva could not finance the tender offer, and the agreement was terminated July 24 with Lisata collecting a $1M breakup fee [10][11]. What remains active is the Qilu-sponsored wind-down Phase 2 in Chinese pancreatic ductal adenocarcinoma (PDAC) patients [2][9], a completed-enrollment Phase 2a in newly diagnosed glioblastoma (LSTA1-GBM-2A) whose protocol was published in BMJ Open in late 2025 [3][12], and roughly $10M of cash as of mid-2026 [11]. The scientific hypothesis is interesting (make the tumor vasculature briefly permeable so chemo can get in), but every prior drug class that tried to break the pancreatic stroma barrier has failed in late-stage trials, and the failed merger plus the Qilu termination say the market and the most informed potential acquirer both priced certepetide close to zero. Watchable in GBM, not in PDAC or biliary.

Novel compound. Peptide therapeutic that has never been approved anywhere. No FDA breakthrough, fast track, or priority designations have been disclosed. Timeline of recent events: (1) BOLSTER Phase 2 in cholangiocarcinoma (NCT05712356) terminated after enrolling 66 patients, with safety as the listed primary endpoint rather than a hard efficacy readout [1]. (2) January 27, 2026: Lisata and Qilu announced mutual termination of their Greater China license agreement originally signed in 2021. All rights reverted to Lisata; Qilu agreed to complete and wind down (not expand) its ongoing Phase 2 trial NCT06261359, which enrolls 120 first-line PDAC patients with objective response rate as primary endpoint [2][9]. Lisata separately agreed to negotiate rights to the resulting trial data, which clarifies the earlier contradiction: Qilu is the trial sponsor on an existing wind-down study, not a continuing development partner. (3) March 2026: Lisata signed a definitive merger agreement with Kuva Labs at $4.00 per share cash plus a non-tradeable CVR worth up to $3.00 per share tied to certepetide milestones (including New Drug Application filing or acceptance for review in any jurisdiction within seven years of closing) [4]. (4) June 10, 2026: Kuva commenced tender offer. (5) July 20, 2026: tender offer expired without extension because Kuva could not obtain the financing; the merger agreement was terminated July 24, 2026, and Lisata received a $1M breakup payment [10][11]. As of October 2026 Lisata remains independent and listed on Nasdaq. (6) LSTA1-GBM-2A: Lisata announced first patient treated in late 2025, 30-patient 2:1 randomized Phase 2a in newly diagnosed glioblastoma across sites in Estonia and Latvia (planned Lithuania), with the protocol formally published in BMJ Open in October 2025 [3][12]. No public readout timeline has been disclosed. Certepetide was originally developed by Cend Therapeutics (founded on Ruoslahti-lab iRGD work) and became Lisata's lead asset through the 2022 Lisata/Cend merger that renamed the combined company Lisata Therapeutics [5].

Think of a solid tumor as a walled fortress. Chemotherapy has to cross dense fibrous tissue (the stroma) and leaky, chaotic blood vessels to reach cancer cells. In pancreatic cancer this stromal barrier is so thick that most systemic drugs never arrive at adequate concentrations. Certepetide is a short cyclic peptide built around the iRGD motif. When it binds NRP1 (neuropilin-1), a receptor on tumor blood vessels, it activates what biologists call the CendR (C-end Rule) pathway. In plain terms, the peptide tells the tumor vasculature to temporarily open a bulk-transport channel. Co-administered drugs then diffuse into the tumor more efficiently without being chemically linked to the peptide itself [5]. The target biology was characterized by the Ruoslahti lab in a 2010 Science paper, roughly 15 years before this writeup, in mouse models of pancreatic cancer where co-administration of iRGD-class peptides raised intratumoral drug concentrations several-fold [5]. The gap between mouse PDAC and human PDAC is where every stromal-targeting approach has died, including PEGPH20 (recombinant hyaluronidase, Halozyme) which failed its Phase 3 HALO-301 trial in 2019 [6]. The mechanism is scientifically defensible but has not been de-risked in humans.

BOLSTER (NCT05712356) tested certepetide plus standard chemotherapy against chemotherapy alone in advanced cholangiocarcinoma. It was terminated after enrolling 66 patients, below the originally planned enrollment, with safety (adverse event rate) as the listed primary endpoint rather than a hard efficacy readout [1]. NCT06261359 is sponsored by Qilu Pharmaceutical in China, enrolling 120 first-line PDAC patients with objective response rate as the primary endpoint; following the January 2026 mutual license termination, Qilu is contractually completing this trial as a wind-down obligation rather than expanding development [2][9]. The glioblastoma Phase 2a (LSTA1-GBM-2A, BMJ Open 2025 protocol) is a double-blind, placebo-controlled, 30-patient 2:1 randomized study of certepetide plus temozolomide in newly diagnosed GBM across sites in Estonia and Latvia; first patient was treated in late 2025 [3][12]. The completed Phase 1 trials (NCT03517176 with nab-paclitaxel plus gemcitabine, NCT05052567 Qilu Phase 1 in metastatic PDAC) supported safety and dose selection [7][8]. Design concerns: all remaining trials add certepetide to standard-of-care, so any efficacy signal must beat the control arm by a meaningful margin to justify a two-drug regimen. The China-only enrollment in NCT06261359 also creates a question about whether the data would support a US or EU filing without a bridging trial, a bridge Lisata (now holding the global rights) would have to run itself. The GBM study is small (n=30) and underpowered for overall survival, so a signal would be hypothesis-generating at best.

Our model estimates a 1% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, its few secondary endpoints, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant concern. Every drug class that has tried to break the pancreatic stromal barrier has failed in late-stage trials, including PEGPH20 (Halozyme) which missed in Phase 3 in 2019 [6], and multiple nab-paclitaxel combinations tested with evofosfamide and other stromal-modulating agents. The CendR mechanism is biologically distinct, but it faces the same translational wall. Execution and financing risk is now the headline. BOLSTER's termination [1], the January 2026 mutual Qilu license termination [9], and the collapse of the Kuva merger in July 2026 [10][11] together look like a sponsor-side wind-down of certepetide as a priority program. Lisata reported $10.4M in cash as of June 30, 2026 against roughly $4M in quarterly operating expenses, with a market cap near $32M at that date [11]. That is burn-rate math that implies a capital raise, a new partnership, or an additional strategic transaction is required within the next 2 to 4 quarters simply to keep the GBM study and other costs funded. Safety has not been a visible issue. Certepetide is a short peptide with limited systemic exposure, and the completed Phase 1 trials (NCT03517176, NCT05052567) did not surface class-wide toxicity concerns [7][8]. Commercial risk, even in a positive readout scenario, is that payers rarely reimburse well for adding a peptide onto existing chemotherapy regimens without a large absolute survival benefit. Two-drug combination pricing in PDAC is already a reimbursement fight.

Noise more than signal at this point. The scientific hypothesis (CendR-mediated tumor penetration) is interesting and defensible, but the clinical and corporate programs have unwound. BOLSTER terminated, Qilu license mutually terminated January 2026 with Qilu only winding down its existing study, and the Kuva Labs acquisition collapsed in July 2026 when Kuva could not finance a $4-plus-CVR tender offer [1][9][10][11]. A CVR (contingent value right) is a payment right that transfers to target shareholders only if a specific milestone is hit (here, NDA filing or acceptance for certepetide within seven years of closing, worth up to $3 per share) [4]. CVRs are typically used when acquirer and seller disagree on asset value, and structuring a deal around one, then walking away from even the upfront cash portion, is the clearest market signal that the acquirer is not paying for certepetide upfront. The one place worth watching is the glioblastoma Phase 2a (LSTA1-GBM-2A), where penetration-enhancing drugs have a less-crowded failure history, temozolomide's modest effect in newly diagnosed GBM leaves room for a measurable signal, and the first patient has already been treated against a small 30-patient target [3][12]. Check back when (a) Lisata announces a new strategic transaction, financing, or partner given the roughly $10M cash position as of mid-2026 [11], (b) the Qilu-sponsored PDAC Phase 2 (NCT06261359) reports interim ORR data on its wind-down [2], or (c) LSTA1-GBM-2A reports interim or final data [12]. Everything else is housekeeping on a program the market has already written down.